A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
9actual
Sites
9
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-30 | actual | When the study began enrolling |
| Primary completion | 2026-07-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumors
- Advanced Solid Tumors
- Metastatic Solid Tumors
Interventions
- Drug: INCB177054
- Drug: Retifanlimab
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with Dose Limiting Toxicities (DLTs)
measured Up to 28 days
Number of participants with Treatment-emergent Adverse Events (TEAEs)
measured Up to approximately 12 months and 45 days
Number of participants with TEAEs leading to study drug modifications
measured Up to approximately 12 months and 45 days
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed